BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05762471 (GSBR-1290 in Overweight or Obesity Type2 Diabetes Mellitus): BVCT ex-ante prediction vs. reported outcome

On 6 Mar 2024, BioinvestGPT's BVCT predicted technical success and commercial partial success for this trial. The 3 Jun 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially insufficient.

Clinical Trial

NCTID
NCT05762471
Drug Name
GSBR-1290
Drug MoA
an oral and biased small molecule GLP1R agonist
Drug Modality
small-molecule
Drug Class
First-In-Class
Therapeutic Area
Nutritional and Metabolic Diseases
Indication
Overweight or Obesity Type2 Diabetes Mellitus
Human Patients
142
Sponsor
Structure Therapeutics
Phase
Phase 1 Phase 2

Prediction of , index 1266

Prospective Prediction
Prediction Index
1266
Prediction Date
Commercial Prediction
partial SUCCESS (commercially insufficient clinical benefit inferior to VK2735 for obesity)
Technical Prediction
SUCCESS (statistically significant clinical benefit in weight loss)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
89 days in advance
Readout Data Interpretation
6.2-6.9% placebo-adjust weight loss at week 12 (vs 13.1% at week 12 by Amycretin (on a par with VK2735) and 6-7% by orforglipron at week 12).
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 1b/2a, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus on Metformin
Phase
Phase 1, Phase 2
Status
Completed
Enrollment
142
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Conditions
Overweight or Obesity; Type2 Diabetes Mellitus
Interventions
DRUG: GSBR-1290; DRUG: Placebo
Design
Randomized · Parallel · Triple
Primary purpose
Treatment
Start
2023-01-09
Primary completion
2024-04-11
Completion
2024-04-11
Primary outcomes
  • Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM (42 days)

NCT05762471 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials